India Anti-Obesity Drug Market Size and Forecast (2024-2030)

Executive Summary

In recent years, the Indian anti-obesity drug market has shown signs of significant growth, driven by the launch of Novo Nordisk’s anti-obesity drug. This trend is expected to continue, with other players, including Eli Lilly, planning to introduce their obesity drugs between 2025 and 2030. Eli Lilly’s Mounjaro, for instance, is set to launch in India in 2025. From 2019 to 2023, the market experienced an impressive compound annual growth rate (CAGR). This growth gained momentum in 2022 following the introduction of semaglutide (Rybelsus) by Novo Nordisk, which marked a breakthrough in obesity management. The launch of this drug led to a 60.11% growth in the market in 2022, with the momentum accelerating further to 65.87% in 2023, highlighting the rapid adoption of semaglutide-based treatments.

The market’s expansion is primarily supported by a growing awareness of obesity-related health complications and an increasing demand for effective solutions. According to the Indian Council of Medical Research's (ICMR)-INDIAB study published in 2023, approximately 10.1 crore individuals in India are living with diabetes. This trend, coupled with an ageing population in certain states, presents significant health challenges and underscores the need for preventive measures and lifestyle interventions to address obesity and its associated risks. The obesity rate in India has seen a sharp rise, increasing from 1.2% in 1990 to 9.8% in 2022 among women and from 0.5% to 5.4% among men during the same period.

Domestic pharmaceutical companies have played a pivotal role in market growth by introducing affordable generic drugs, including biosimilars of established GLP-1 receptor agonists such as liraglutide. In 2024, Glenmark Pharmaceuticals launched Lirafit, a biosimilar version of liraglutide, while Sun Pharma announced promising phase 1 results for its GLP-1-based obesity drug, GL0034, in 2023.

Despite these advancements, the market faces challenges, including limited awareness and regulatory hurdles. The adoption of anti-obesity drugs remains concentrated among affluent urban populations, with off-label use of diabetes medications like semaglutide and liraglutide dominating the market.

The Indian anti-obesity drug market holds significant potential for growth, driven by rising health awareness, the introduction of new products, and government efforts to support domestic manufacturing through production-linked incentive (PLI) schemes. However, sustained growth will depend on addressing regulatory challenges, increasing affordability, and enhancing awareness across diverse population segments.

Future Outlook of India Anti-Obesity Drug Market:

The Indian anti-obesity drug market is poised for significant growth, driven by rising awareness of obesity-related health issues, rapid urbanization, higher disposable incomes, and the increasing prevalence of obesity and diabetes. This growth is underpinned by the market’s projected CAGR of double digit in next five years, as GLP-1 drugs, originally approved for diabetes treatment, gain recognition for their weight-loss benefits through mechanisms like delayed digestion.

India’s government is set to enhance local manufacturing capabilities for GLP-1 drugs by 2026 through production-linked incentive (PLI) schemes, encouraging the development of cost-effective generic alternatives. The expiration of Novo Nordisk's semaglutide patent in 2026 is expected to lower prices, further expanding accessibility and market opportunities.

Domestic pharmaceutical companies, particularly those specializing in antidiabetic drugs, are well-positioned to capitalize on these developments by introducing affordable alternatives, boosting market penetration. The market will also see the introduction of new drugs, including Eli Lilly's Tirzepatide in 2025 and Wegovy (semaglutide) in 2026, creating more options for consumers.

Despite strong market growth, the influx of generics and the entry of both domestic and international players are expected to intensify competition, leading to a decline in average drug prices. Nevertheless, economic growth, rising per capita incomes, and increased health awareness will sustain market expansion, driving higher consumption volumes in the coming years.

Scope of India Anti-Obesity Drug Market Report:

Makreo Research has published an extensive report titled “India Anti-Obesity Drug Market,” offering a detailed analysis of the country’s evolving market landscape. The report examines the impact of economic, political, technological, and demographic factors on market dynamics, while assessing historical and current market performance. It also evaluates global obesity trends, comparing them with those in India to analyze their influence on market growth.

The study also provides a thorough competitive analysis, including profiles of leading market players, and explores the availability, approval status, and anticipated launches of various drugs in India. It offers a segmentation breakdown, highlighting key insights such as market share, segment-specific performance, and prevailing trends. Furthermore, the report identifies significant challenges facing the market and uncovers growth opportunities that are expected to drive its expansion. This comprehensive research serves as a valuable resource for stakeholders and industry professionals, delivering critical insights into India’s fast-growing anti-obesity drug market.

Period of Study:

• 2019 - 2023: Past and Present Scenario
• 2023: Base year of study
• 2024 – 2030: Future Outlook

Market Assessment

The report offers a comprehensive analysis of India's anti-obesity drug market, covering essential aspects such as drug approvals, market availability, historical and current performance, and alternatives to the market etc. It also reviews global obesity trends, comparing them to India's scenario to assess their market impact, along with an in-depth segmentation analysis. Furthermore, the report delves into market dynamics, emphasizing the key drivers and challenges shaping the industry. It concludes with a future outlook for both the global and Indian markets, identifying the critical factors likely to propel growth in the years ahead.

Market Segmentation:

• By Drug Type
• By Administration Route
• By Drug Classification
• By Distribution Channels
• By Regions

Competitive Landscape

This section provides a detailed market comparison of key players in the India anti-obesity drug market based on various parameters. It also highlights their recent investments, merges and acquisitions (M&A), and funding activities in the market. Additionally, it includes comprehensive profiles of selected industry players, covering their financials and latest business activities.

Companies Covered:

• Aristo Pharmaceuticals Pvt. Ltd.
• Mankind Pharmaceuticals
• Torrent Pharmaceuticals Limited
• Biocon Pharmaceuticals
• Sun Pharmaceuticals Industries Ltd.
• Dr.Reddy's Laboratories Ltd.
• Cipla Limited
• Divi's Laboratories
• Novo Nordisk
• Eli Lilly and Company
• Eris Lifesciences
• Leeford Healthcare
• Lupin Limited.

Key Questions Answered

1. How has the India anti-obesity drug market performed historically, and what is the current scenario?

2. How do economic, political, technological, and demographic conditions impact the India anti-obesity drug market?

3. What is the global prevalence of obesity, how does it compare to India's obesity rates, and what differences exist between the two?

4. What is the approval status of various anti-obesity drugs in Indian market?

5. How does the availability of anti-obesity drugs in the Indian market differ across various parameters?

6. Which anti-obesity drugs have been recently launched in India, and what new launches are anticipated in the near future?

7. Who are the key players in the India anti-obesity drug market?

8. What are the market shares of the major companies in this segment?

9. How do the leading companies compare across parameters like revenue, market share, and price to sales ratio etc.?

10. What are the major challenges associated with the market?

11. What are the key drivers for growth of the India anti-obesity drug market?

12. What is the future outlook for the India anti-obesity drug market and what opportunities are associated with it? Show more